Biomark Diagnostics (Biomark Diagnostics) Debt-to-Equity : -1.94 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biomark Diagnostics Debt-to-Equity?

Biomark Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.40 Mil. Biomark Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.41 Mil. Biomark Diagnostics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-0.42 Mil. Biomark Diagnostics's debt to equity for the quarter that ended in Dec. 2023 was -1.94.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biomark Diagnostics's Debt-to-Equity or its related term are showing as below:

BMKDF' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.37 Med: -0.8 Max: -0.01
Current: -1.94

During the past 10 years, the highest Debt-to-Equity Ratio of Biomark Diagnostics was -0.01. The lowest was -2.37. And the median was -0.80.

BMKDF's Debt-to-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.22 vs BMKDF: -1.94

Biomark Diagnostics Debt-to-Equity Historical Data

The historical data trend for Biomark Diagnostics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Debt-to-Equity Chart

Biomark Diagnostics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

-0.02

-1.52

-1.65

-0.72

Biomark Diagnostics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-1.05	-0.72	-0.65	-0.45	-1.94

Competitive Comparison of Biomark Diagnostics's Debt-to-Equity

For the Diagnostics & Research subindustry, Biomark Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomark Diagnostics's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's Debt-to-Equity falls into.

Biomark Diagnostics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biomark Diagnostics's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.443	+	0.159)	/	-0.84
	=	-0.72

Biomark Diagnostics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.4	+	0.408)	/	-0.417
	=	-1.94

Biomark Diagnostics (OTCPK:BMKDF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biomark Diagnostics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomark Diagnostics (Biomark Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BUX:Canada

Address

130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2

Website

https://www.biomarkdiagnostics.com

Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (Biomark Diagnostics) Headlines

No Headlines